Second order for Biacore A100 comes from a major European-based pharmaceutical company, which intends to utilise the system to enhance its bio-therapeutic screening capabilities
Biacore reports further commercial progress with Biacore A100, its most advanced array system for protein interaction analysis.
It has received its second order for Biacore A100 from a major European-based pharmaceutical company, which intends to utilise the system to enhance its bio-therapeutic screening capabilities.
In addition, Biacore A100 was highlighted at the Developments in Protein Interaction Analysis Conference (Dipia) on 28-31 August 2005 in Philadelphia, USA.
The Dipia conference, sponsored by Biacore, offered the more than 300 participants the opportunity to exchange and discuss information on new applications and specific methodologies in protein interaction analysis.
At the conference a number of papers were presented, both by academic and industrial researchers, which highlighted the unique data that can be generated using Biacore A100 for a range of small molecule and antibody screening applications.
Organisations which made presentations on working with BiacoreA100 were the University of Utah, Hoffman La-Roche, Glaxo SmithKline and the National Institute of Advanced Industrial Science and Technology (AIST), Japan.
Biacore will also showcase Biacore A100 at two upcoming European conferences.
The first is Hupo 4th annual world conference, 28 August to 1 September in Munich, Germany, and the second is the SBS 11th annual conference and exhibition in Geneva, Switzerland from 11-15 September where Biacore, as one of the sponsors, will also run a tutorial session on the applications of Biacore A100.
These industry events also marked the product's planned roll-out to the company's mainstream sales force.
Previously the system had been marketed by a dedicated team comprising both business development and research personnel.
This more extensive marketing of Biacore A100 is expected over time to lead to a further penetration of the academic and industrial markets for the product.
Erik Wallden, Biacore's president and CEO said: "I am pleased to announce Biacore's second commercial order for Biacore A100 to a major pharmaceutical company.
"The introduction of this powerful new product using a small specialist team is now successfully concluded, and the commercialisation of Biacore A100 is now in a new phase being marketed through our regular marketing and sales personnel.
"The exciting screening data which was presented at the Dipia, Hupo and SBS conferences is the result of a number of very successful academic and industrial collaborations and will greatly assist Biacore's general sales force in creating further commercial interest in this exciting product".
A complete programme covering all of the presentations at the developments in protein interaction analysis conference (Dipia) is available from the Biacore website.
Biacore A100 has been designed and developed for use in a broad range of applications in proteomics, early kinetic screening of antibody therapeutics and in many areas within drug discovery including hit validation, compound library screening particularly from virtual screens and fragment libraries, lead optimisation and also in pre-clinical studies.
Biacore A100 rapidly monitors protein interactions (thousands of interactions per day) to generate high quality kinetic, affinity and selectivity of binding information.
Biacore A100 enables multiplex kinetic screening of protein panels providing unique selectivity information.
The parallel real-time analysis of protein interactions combining increased throughput, with the sensitivity needed to handle small molecule analysis.
The array technology brings a new dimension to the study of protein interactions by using parallel analysis to generate crucial information on the behavior and interactions of a wide range of proteins grouped into panels or other configurations.
The system also includes new software tools that have been optimised for array applications and are designed to handle large data volumes.
Biacore is a global supplier of analytical systems that improve the productivity of research and development in the life science and pharmaceutical markets.
The company's instruments generate unique data on protein interactions, an area of increasing focus in these markets.
The data give insights into protein functionality, the role of proteins in normal and diseased states, and the influence of potential drug candidates.
Use of Biacore products is well-documented in key areas such as antibody characterisation, proteomics, lead optimisation and bio-therapeutic development and production.
Customers include world renowned life science research centers, all of the leading global pharmaceutical companies and a large number of companies in the emerging biotechnology sector.
Biacore is successfully expanding into the food analysis market, providing key manufacturers with ready-to-use solutions for the determination of food quality and safety.
The company offers a range of products to meet specific customer needs.
All instruments utilise surface plasmon resonance (SPR) technology as the basis for detection and monitoring of protein interactions.
Biacore has its own direct sales capability in the world's key markets, United States, Europe, Japan, Australia and a distribution network in Asia-Pacific.
The company was created in 1984, is based in Uppsala, Sweden, and is listed on the Stockholm Stock Exchange.
